Journals / Turkish Journal of Urology / 2022 / Cilt: 48 - Sayı: 3

Comprehensive Review on Current Controversies and Debate in Prostate Artery Embolization

Pages
166–173
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These factors are the most pressing faced by proponents of prostate artery embolization, and we seek to highlight why their resolution is important to ensure men with benign prostate hyperplasia seeking a minimally invasive solution are optimally informed and most effectively managed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prostate artery embolization is emerging as one of the most effective therapies amidst a new era of mini- mally invasive benign prostate hyperplasia treatment and technology.
📊
Key Findings & Data:However, several current controver- sies remain unanswered which could impact the widespread adoption of this novel and unique transarterial (rather than transurethral) intervention.
💡
Conclusion & Impact:These factors are the most pressing faced by proponents of prostate artery embolization, and we seek to highlight why their resolution is important to ensure men with benign prostate hyperplasia seeking a minimally invasive solution are optimally informed and most effectively managed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Prostate artery embolization is emerging as one of the most effective therapies amidst a new era of mini- mally invasive benign prostate hyperplasia treatment and technology. However, several current controver- sies remain unanswered which could impact the widespread adoption of this novel and unique transarterial (rather than transurethral) intervention. This is reflected in the differences between the UK (NICE), European (EAU), and American (AUA) guidelines, the latter of which only recommends the use of prostate artery embolization in a clinical trial setting. The main issues include questions over the duration of symptom response, cost-effectiveness, mechanism of action, patient selection, and other procedural technical consid- erations. These factors are the most pressing faced by proponents of prostate artery embolization, and we seek to highlight why their resolution is important to ensure men with benign prostate hyperplasia seeking a minimally invasive solution are optimally informed and most effectively managed.

🔖

Cite This Article

MACLEAN, D., BRYANT, C. T. F., VİGNESWARAN, G., BRYANT, T. J., HARRİS, M., SOMANİ, B., MODİ, S. (2022). Comprehensive Review on Current Controversies and Debate in Prostate Artery Embolization. Turkish Journal of Urology, Cilt: 48 - Sayı: 3, 166–173. https://ajindex.com/articles/413236

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Egan KB. The epidemiology of benign prostatic hyperplasia asso- ciated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016
  2. 43(3):289-297. [CrossRef] 2. Pascoe J, Fontaine C, Hashim H. Modern advancements in mini- mally invasive surgical treatments for benign prostatic obstruction. Ther Adv Urol. 2021
  3. 17562872211030832. [CrossRef] 3. Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising world- wide impact of benign prostatic hyperplasia. BJU Int. 2021
  4. 127(6):722-728. [CrossRef] 4. Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of pro- static artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018
  5. k2338. [CrossRef] 5. Kaplan SA. Re: randomised Clinical Trial of Prostate artery Embo- lisation versus a Sham Procedure for benign prostatic Hyperplasia [internet]. J Urol. 2020
  6. 204(2):357-358. [CrossRef] 6. Knight GM, Talwar A, Salem R, Mouli S. Systematic review and meta-analysis comparing prostatic artery embolization to gold- standard transurethral resection of the prostate for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2021
  7. 44(2):183-193. [CrossRef] 7. Zhou Z, Gao Z, Wu J, Cui Y. Transurethral resection of the pros- tate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. World J Urol. 2020
  8. 38(8):2069-2070. [CrossRef] 8. Jiang YL, Qian LJ. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. BMC Urol. 2019
  9. 19(1):11. [CrossRef] 9. NICE Guidance - Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia: © NICE (2018) Prostate artery embolisation for lower urinary tract symp- toms caused by benign prostatic hyperplasia. BJU Int. 2018
  10. 122(1):11-12. [CrossRef] 10. Mayor S. NICE recommends prostate artery embolisation as a treatment option for BPH symptoms. BMJ. 2018
  11. k1879. [CrossRef] 11. McWilliams JP, Kuo MD, Rose SC, et al. Society of Interventional Radiology position statement: prostate artery embolization for treatment of benign disease of the prostate [internet]. J Vasc Interv Radiol. 2014
  12. 25(9):1349-1351. [CrossRef] 12. Martins Pisco J, Pereira J, Rio Tinto H, Fernandes L, Bilhim T. How to perform prostatic arterial embolization. Tech Vasc Interv Radiol. 2012
  13. 15(4):286-289. [CrossRef] 13.